NCT01060150
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
See it on ClinicalTrials.gov ↗113 people
23.9%
76.1%
27 womenmiddle line = equal numbers86 men
- Phase
- PHASE4
- Paid for by
- Janssen Korea, Ltd., Korea
- Finished
- 2010-04
- Health conditions
- Attention Deficit Disorder With Hyperactivity
- Who could join
- Anyone
- Ages
- 12 Years – 18 Years
- Average age
- mean 15.24 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 18 Years.”
- No seizures
Women with epilepsy or past seizures were turned away.
“…der ordiagnosed with an overall developmental disorder, organic brain disorder, seizure (sudden, uncontrolled muscle spasms and loss of consciousness resulting from abnormal brain function) disorder, movement disorder requiring the medicati…”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Participants diagnosed with major depression or anxiety disorders according to DSM-IV Diagnostic criteria and who requires drug therapy”
Study titles and rules are shown in their original English.